Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review
Rosalba Camicia, Hans Christian Winkler, Paul O. Hassa
Molecular Cancer (2015) Vol. 14, Iss. 1
Open Access | Times Cited: 150

Showing 1-25 of 150 citing articles:

Structural Basis for Potency and Promiscuity in Poly(ADP-ribose) Polymerase (PARP) and Tankyrase Inhibitors
A.G. Thorsell, T. Ekblad, T. Karlberg, et al.
Journal of Medicinal Chemistry (2016) Vol. 60, Iss. 4, pp. 1262-1271
Open Access | Times Cited: 329
Diffuse large B-cell lymphoma: R-CHOP failure—what to do?
Bertrand Coiffier, Clémentine Sarkozy
Hematology (2016) Vol. 2016, Iss. 1, pp. 366-378
Open Access | Times Cited: 233
CD20-TCB with Obinutuzumab Pretreatment as Next-Generation Treatment of Hematologic Malignancies
Marina Bacac, Sara Colombetti, Sylvia Herter, et al.
Clinical Cancer Research (2018) Vol. 24, Iss. 19, pp. 4785-4797
Open Access | Times Cited: 183
Impact of Expert Pathologic Review of Lymphoma Diagnosis: Study of Patients From the French Lymphopath Network
Camille Laurent, Marine Baron, Nadia Amara, et al.
Journal of Clinical Oncology (2017) Vol. 35, Iss. 18, pp. 2008-2017
Closed Access | Times Cited: 177
Inhibitors of immune checkpoints—PD-1, PD-L1, CTLA-4—new opportunities for cancer patients and a new challenge for internists and general practitioners
Marek Z. Wojtukiewicz, Magdalena M. Rek, Kamil Karpowicz, et al.
Cancer and Metastasis Reviews (2021) Vol. 40, Iss. 3, pp. 949-982
Open Access | Times Cited: 165
CREBBP/EP300 mutations promoted tumor progression in diffuse large B-cell lymphoma through altering tumor-associated macrophage polarization via FBXW7-NOTCH-CCL2/CSF1 axis
Yao‐Hui Huang, Kun Cai, Pengpeng Xu, et al.
Signal Transduction and Targeted Therapy (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 144
Pre-clinical pharmacology of AZD3965, a selective inhibitor of MCT1: DLBCL, NHL and Burkitt’s lymphoma anti-tumor activity
Nicola J. Curtis, Lorraine Mooney, Lorna Hopcroft, et al.
Oncotarget (2017) Vol. 8, Iss. 41, pp. 69219-69236
Open Access | Times Cited: 130
PD-L1 expression on neoplastic or stromal cells is respectively a poor or good prognostic factor for adult T-cell leukemia/lymphoma
Hiroaki Miyoshi, Junichi Kiyasu, Takeharu Kato, et al.
Blood (2016) Vol. 128, Iss. 10, pp. 1374-1381
Open Access | Times Cited: 119
Outcomes of diffuse large B-cell lymphoma patients relapsing after autologous stem cell transplantation: an analysis of patients included in the CORAL study
Éric Van Den Neste, Norbert Schmitz, Nicolas Mounier, et al.
Bone Marrow Transplantation (2016) Vol. 52, Iss. 2, pp. 216-221
Open Access | Times Cited: 117
How to Hit Mesenchymal Stromal Cells and Make the Tumor Microenvironment Immunostimulant Rather Than Immunosuppressive
Alessandro Poggi, Serena Varesano, Maria Raffaella Zocchi
Frontiers in Immunology (2018) Vol. 9
Open Access | Times Cited: 99
A Review of Autologous Stem Cell Transplantation in Lymphoma
Umar Zahid, Faisal Akbar, Akshay Amaraneni, et al.
Current Hematologic Malignancy Reports (2017) Vol. 12, Iss. 3, pp. 217-226
Open Access | Times Cited: 93
Genetic and epigenetic determinants of diffuse large B-cell lymphoma
Tanner J. Bakhshi, Philippe T. Georgel
Blood Cancer Journal (2020) Vol. 10, Iss. 12
Open Access | Times Cited: 80
Integrated precision medicine: the role of electronic health records in delivering personalized treatment
Amy M. Sitapati, Hyeoneui Kim, Barbara Berkovich, et al.
WIREs Systems Biology and Medicine (2017) Vol. 9, Iss. 3
Open Access | Times Cited: 68
Avadomide monotherapy in relapsed/refractory DLBCL: safety, efficacy, and a predictive gene classifier
Cecilia Carpio, Réda Bouabdallah, Loïc Ysebaert, et al.
Blood (2020) Vol. 135, Iss. 13, pp. 996-1007
Open Access | Times Cited: 61
Application of NanoString technologies in companion diagnostic development
Jennifer Mary Eastel, Ka Wai Lam, Nga Lam Lee, et al.
Expert Review of Molecular Diagnostics (2019) Vol. 19, Iss. 7, pp. 591-598
Closed Access | Times Cited: 58
Sirt6 promotes tumorigenesis and drug resistance of diffuse large B-cell lymphoma by mediating PI3K/Akt signaling
Juan Yang, Ying Li, Ya Zhang, et al.
Journal of Experimental & Clinical Cancer Research (2020) Vol. 39, Iss. 1
Open Access | Times Cited: 58
Iron oxide nanoparticles inhibit tumor growth by ferroptosis in diffuse large B-cell lymphoma.
Qi-Tang Huang, Quan-Quan Hu, Zhao-Feng Wen, et al.
PubMed (2023) Vol. 13, Iss. 2, pp. 498-508
Closed Access | Times Cited: 18
Mesenchymal Stromal Cells Can Regulate the Immune Response in the Tumor Microenvironment
Alessandro Poggi, Massimo Giuliani
Vaccines (2016) Vol. 4, Iss. 4, pp. 41-41
Open Access | Times Cited: 60
Aberrant methylation of cell-free circulating DNA in plasma predicts poor outcome in diffuse large B cell lymphoma
Lasse S. Kristensen, Jakob Werner Hansen, Søren Sommer Kristensen, et al.
Clinical Epigenetics (2016) Vol. 8, Iss. 1
Open Access | Times Cited: 54
The tumor suppressive TGF-β/SMAD1/S1PR2 signaling axis is recurrently inactivated in diffuse large B-cell lymphoma
Anna Stelling, Hind Hashwah, Katrin Bertram, et al.
Blood (2018) Vol. 131, Iss. 20, pp. 2235-2246
Open Access | Times Cited: 54
Discovery and Optimization of Pyrrolopyrimidine Inhibitors of Interleukin-1 Receptor Associated Kinase 4 (IRAK4) for the Treatment of Mutant MYD88L265P Diffuse Large B-Cell Lymphoma
James S. Scott, Sébastien L. Degorce, Rana Anjum, et al.
Journal of Medicinal Chemistry (2017) Vol. 60, Iss. 24, pp. 10071-10091
Closed Access | Times Cited: 50
Genetic Insights into Breast Cancer in Northeastern Mexico: Unveiling Gene–Environment Interactions and Their Links to Obesity and Metabolic Diseases
Hugo L. Gallardo‐Blanco, María Lourdes Garza-Rodríguez, Diana Cristina Pérez-Ibave, et al.
Cancers (2025) Vol. 17, Iss. 6, pp. 982-982
Open Access
Anthracycline dose optimisation in patients with diffuse large B-cell lymphoma: a multicentre, phase 3, randomised, controlled trial
Pengpeng Xu, Di Fu, Jianyong Li, et al.
The Lancet Haematology (2019) Vol. 6, Iss. 6, pp. e328-e337
Closed Access | Times Cited: 40
Proteasomal cysteine deubiquitinase inhibitor b-AP15 suppresses migration and induces apoptosis in diffuse large B cell lymphoma
Liling Jiang, Yuening Sun, Jinxiang Wang, et al.
Journal of Experimental & Clinical Cancer Research (2019) Vol. 38, Iss. 1
Open Access | Times Cited: 35
Biomimetic nanotherapy: core–shell structured nanocomplexes based on the neutrophil membrane for targeted therapy of lymphoma
Qiangqiang Zhao, Duanfeng Jiang, Xiaoying Sun, et al.
Journal of Nanobiotechnology (2021) Vol. 19, Iss. 1
Open Access | Times Cited: 28
Page 1 - Next Page

Scroll to top